HMG CoA reductase inhibition by Simvastatin gets rat β-Myosin heavy chain disappeared: A statin paradox


3-hydroxy-3methylglutaryl Coenzyme A reductase, the rate limiting enzyme of mevalonate pathway, generates, in addition to cholesterol, a range of products involved in several biological functions: oligoprenyl groups, dolichol and ubiquinone. The latter, in particular, participates in electron transport chain and, in turn, in tissue energy supply. The enzyme is inhibited by statins that, besides lowering cholesterolemia, seem to impair human energy-dependent myocardial functions (e.g. stroke volume, cardiac output, and contractile index). The modulation of heart contractile properties could be explained by the decrease of ventricle ubiquinone content and/or by putative changes in proportion of the different myosin heavy chain isoforms. Since we previously demonstrated that chronic statin treatment modifies myosin heavy chain isoform pattern in skeletal muscle impairing its functional properties, this work was aimed at investigating the effects of statin chronic treatment on both ventricle ubiquinone content and myosin heavy chain isoforms. Our results showed that simvastatin treatment leads to a reduced amount of rat ventricle ubiquinone and to β myosin heavy chain disappearance. Thus, statins which are prescribed to prevent cardiovascular disease, might induce cardiac metabolic and structural modifications whose functional implications on contractility are still to be established and carefully considered.

Share and Cite:

Trapani, L. , Segatto, M. , Jozwiak, A. , Swiezewska, E. and Pallottini, V. (2013) HMG CoA reductase inhibition by Simvastatin gets rat β-Myosin heavy chain disappeared: A statin paradox. Open Journal of Molecular and Integrative Physiology, 3, 1-5. doi: 10.4236/ojmip.2013.31001.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Goldstein, J.L. and Brown, M.S. (1990) Regulation of the mevalonate pathway. Nature, 343, 425-430. doi:10.1038/343425a0
[2] Draeger, A., Monastyrskaya, K., Mohaupt, M., Hoppeler, H., Savolainen, H., Allemann, C. and Babiychuk, E.B. (2006) Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. Journal of Pathology, 210, 94-102. doi:10.1002/path.2018
[3] Trapani, L., Melli, L., Segatto, M., Trezza, V., Campolongo, P., Jozwiak, A., Swiezewska, E., Pucillo, L.P., Moreno, S., Fanelli, F., Linari, M. and Pallottini, V. (2011) Effects of myosin heavy chain (MHC) plasticity induced by HMGCoA-reductase inhibition on skeletal muscle functions. FASEB Journal, 25, 4037-4047. doi:10.1096/fj.11-184218
[4] Lecomte, V., Meugnier, E., Euthine, V., Durand, C., Freyssenet, D., Nemoz, G., Rome, S., Vidal, H. and Lefai, E. (2009) A new role for sterol regulatory element binding protein 1 transcription factors in the regulation of muscle mass and muscle cell differentiation. Molecular and Cellular Biology, 30, 1182-1198. doi:10.1128/MCB.00690-09
[5] Heynekamp, J.J., Hunsaker, L.A., Vander Jagt, T.A., Royer, R.E., Deck, L.M. and Vander Jagt, D.L. (2008) Isocoumarin-based inhibitors of pancreatic cholesterol esterase. Bioorganic & Medicinal Chemistry, 16, 5285-5294. doi:10.1016/j.bmc.2008.03.016
[6] Trapani, L. and Pallottini, V. (2010) Age-related hypercholesterolemia and HMG-CoA reductase dysregulation: Sex does matter (a gender perspective). Current Gerontology and Geriatrics Research, 2010, 420139. doi:10.1155/2010/420139
[7] Golomb, B.A. and Evans, M.A. (2008) Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. American Journal of Cardiovascular Drugs, 8, 373-418. doi:10.2165/0129784-200808060-00004
[8] Pisarenko, O.I., Studneva, I.M., Lankin, V.Z., Konovalova, G.G., Tikhaze, A.K., Kaminnaya, V.I. and Belenkov, Y.N. (2001) Inhibitor of beta-hydroxy-beta-methylglutaryl coenzyme A reductase decreases energy supply to the myocardium in rats. Bulletin of Experimental Biology and Medicine, 132, 956-958. doi:10.1023/A:1013611110134
[9] Nawarskas, J.J. (2005) HMG-CoA reductase inhibitors and coenzyme Q10. Cardiology in Review, 13, 76-79.
[10] Morkin, E. (2000) Control of cardiac myosin heavy chain gene expression. Microscopy Research and Technique, 50, 522-531. doi:10.1002/1097-0029(20000915)50:6<522::AID-JEMT9>3.0.CO;2-U
[11] Hoh, J.F., McGrath, P.A. and Hale, P.T. (1978) Electrophoretic analysis of multiple forms of rat cardiac myosin: Effects of hypophysectomy and thyroxine replacement. Journal of Molecular and Cellular Cardiology, 10, 1053-1076. doi:10.1016/0022-2828(78)90401-7
[12] Swynghedauw, B. (1986) Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. Physiological Review, 66, 710-771.
[13] Izumo, N., Fujita, T., Nakamuta, H. and Koida, M. (2001) Lipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1- and BMP-2-independent manner. Methods and Findings in Experimental and Clinical Pharmacology, 23, 389-394. doi:10.1358/mf.2001.23.7.662123
[14] Kakinuma, Y., Miyauchi, T., Suzuki, T., Yuki, K., Murakoshi, N., Goto, K. and Yamaguchi, I. (2002) Enhancement of glycolysis in cardiomyocytes elevates endothelin-1 expression through the transcriptional factor hypoxia-inducible factor-1 alpha. Clinical Science (London), 103, 210S-214S.
[15] Krenz, M., Sadayappan, S., Osinska, H.E., Henry, J.A., Beck, S., Warshaw, D.M. and Robbins, J. (2007) Distribution and structure-function relationship of myosin heavy chain isoforms in the adult mouse heart. Journal of Biological Chemistry, 282, 24057-24064. doi:10.1074/jbc.M704574200
[16] Trapani, L., Segatto, M., La Rosa, P., Fanelli, F., Moreno, S., Marino, M. and Pallottini, V. (2012) 3-hydroxy 3- methylglutaryl coenzyme a reductase inhibition impairs muscle regeneration. Journal of Cellular Biochemistry, 113, 2057-2063. doi:10.1002/jcb.24077

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.